Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector
著者
書誌事項
Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector
National Academy Press, 1995
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Committee chairman: Laurence E. Earley
Support for this study was provided by the National Institute on Drug Abuse
Includes bibliographical references
内容説明・目次
内容説明
Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.
Table of Contents
Front Matter
Executive Summary
1 Introduction
2 Overview of the State of Scientific Knowledge Concerning Drug
Addiction
3 Assessment of the Medications Development Division
4 Treatment Setting and Effectiveness
5 Treatment Financing and Trends in Health Insurance
6 Training and Education
7 Federal Laws and Regulations
8 State Laws and Regulations
9 Market Obstacles and Creating Incentives
Appendix A: Acknowledgments
Appendix B: Organization and Mission Statements of NIDA's
Medications Development Division and Its Branches
Appendix C: Diagnostic Criteria for Psychoactive Substance
Dependence
Appendix D: Survey of Pharmaceutical Companies
Appendix E: Model Federal Programs in Pharmaceutical R&D
Appendix F: Workshop Agenda and Participants
Appendix G: Health Care Reform Legislation
Appendix H: Acronyms
目次
- 1 Front Matter
- 2 Executive Summary
- 3 1 Introduction
- 4 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction
- 5 3 Assessment of the Medications Development Division
- 6 4 Treatment Setting and Effectiveness
- 7 5 Treatment Financing and Trends in Health Insurance
- 8 6 Training and Education
- 9 7 Federal Laws and Regulations
- 10 8 State Laws and Regulations
- 11 9 Market Obstacles and Creating Incentives
- 12 Appendix A: Acknowledgments
- 13 Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches
- 14 Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence
- 15 Appendix D: Survey of Pharmaceutical Companies
- 16 Appendix E: Model Federal Programs in Pharmaceutical R 17 Appendix F: Workshop Agenda and Participants
- 18 Appendix G: Health Care Reform Legislation
- 19 Appendix H: Acronyms
「Nielsen BookData」 より